AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website | For Healthcare Professionals Outside the U.S. | US Residents
Thank You for Sharing AFINITOR.com With a Colleague
After clicking the send button below, your colleague will receive an e-mail from you containing an Internet link to this page.
All fields are required.
The e-mail addresses you furnish will be used solely to notify the recipient of the link to this page and that you have requested it be sent. The addresses will not be retained or reused. Learn more about our Privacy Policy.
